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Rousseau P, Tartas M, Fromy B, Godon A, Custaud M-A,
Saumet JL, Abraham P. Platelet inhibition by low-dose aspirin
but not by clopidogrel reduces the axon-reflex current-induced
vasodilation in humans. Am J Physiol Regul Integr Comp Phys-
iol 294: R1420–R1426, 2008. First published February 6, 2008;
doi:10.1152/ajpregu.00810.2007.—We previously showed a pro-
longed inhibition of current-induced vasodilation (CIV) after a single
oral high dose of aspirin. In this study, we tested the hypothesis of
platelet involvement in CIV. Nine healthy volunteers took 75 mg
aspirin/day, 98 mg of clopidogrel bisulfate/day, or placebo for 4 days.
CIV was induced by two consecutive 1-min anodal current applica-
tions (0.08 mA/cm2) through deionized water with a 10-min interval.
CIV was measured with laser Doppler flowmetry and expressed as a
percentage of baseline cutaneous vascular conductance: %Cb. In a
second experiment in 10 volunteers, aspirin and placebo were given as
in experiment 1, but a 26-h delay from the last aspirin intake elapsed
before ACh iontophoresis and postocclusive hyperemia were studied
in parallel to CIV. In experiment 1, the means SE amplitude of CIV
was 822  314, 313  144, and 746  397%Cb with placebo, aspirin
(P  0.05 from placebo and clopidogrel), and clopidogrel (NS from
placebo), respectively. In experiment 2, CIV impairment with aspirin
was confirmed: CIV amplitudes were 300  99, and 916  528%Cb
under aspirin and placebo, respectively (P  0.05), whereas vasodi-
lation to ACh iontophoresis (322  74 and 365  104%Cb) and peak
postocclusive hyperemia (491  137 and 661  248%Cb) were not
different between aspirin and placebo, respectively. Low-dose aspirin,
even 26 h after oral administration, impairs CIV, while ACh-mediated
vasodilation and postocclusive hyperemia are preserved. If platelets
are involved in the neurovascular mechanism triggered by galvanic
current application in humans, it is likely to occur through the
cyclooxygenase but not the ADP pathway.
microcirculation; axon reflex; platelets; skin
A SIGNIFICANT INCREASE IN skin blood flow (SkBF) has been
observed in response to non-noxious galvanic current applica-
tion in humans. This current-induced vasodilation (CIV) has
been described as the result of an axon reflex (3) and disap-
pears in locally anesthetized or chronically capsaicin-treated
skin. Then CIV depends on capsaicin-sensitive fibers and is an
interesting model of the neurovascular interaction following
non-noxious stimulation (11, 16). Prostaglandins are synthe-
sized by cyclooxygenases (COX) and play a key role as
mediators in the vascular response observed during CIV. COX
are expressed in a large variety of human tissues, including
endothelium, smooth muscles, nerves, and platelets (29). We
recently reported a long-lasting inhibition of CIV (5 days)
following a single high (1,000 mg) oral dose of aspirin (11, 12,
40), which irreversibly blocks both isoforms of COX (COX-1
and COX-2). COX of neuronal origin does not seem respon-
sible for this long-lasting effect (13). This long-lasting inhibi-
tion of CIV is consistent with the time required to resynthesize
unblocked platelets after oral single-dose aspirin leading to the
hypothesis that platelets participate in the vascular response to
CIV. Indeed, a single oral high dose of aspirin irreversibly
inactivates the platelet COX pathway for the duration of the
life of the platelets (10 days) (1, 36). Indomethacin, a
nonspecific COX inhibitor devoid of effect on vanilloid recep-
tors and acid-sensing ion channels (41), abolished CIV, con-
firming that the inhibition of CIV by aspirin likely resulted
from its effect on COX (and not on vanilloid receptors or on
acid-sensing ion channels). Furthermore, the specific COX-2
inhibitor, celecoxib, failed to affect CIV, suggesting that CIV
is mainly a COX-1-dependent phenomenon (39).
Together, with the long-lasting effect of a single oral high
dose of aspirin, the fact that COX-1 isoform participates in
CIV raises the question of a possible platelet involvement in
the axon-reflex CIV. Although there is, to date, no in vivo
proof of a direct platelet-mediated vasodilation in humans, the
hypothesis of a platelet involvement in axon-reflex vasodila-
tion and other vasodilator mechanisms has previously been
explored in vitro (15, 23, 31). Those authors provided evidence
for a direct in vitro platelet-mediated endothelium-dependent
vasodilation in preconstricted arteries but mainly by the ADP
pathway.
To investigate whether the platelet COX and ADP pathways
are involved in vivo in CIV, we inhibited platelet function by
aspirin (a platelet COX inhibitor) or clopidogrel (a platelet
ADP-receptor inhibitor). Our hypothesis was that if platelets
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are involved, both clopidogrel and low-dose aspirin would
impair the current-induced vasodilation.
MATERIALS AND METHODS
Healthy nonsmoking volunteers without clinical signs or risk fac-
tors for neural and vascular disease were recruited to participate in this
institutionally approved study conducted in accordance with the
Declaration of Helsinki and registered in the U.S. National Institutes
of Health Web site under reference NCT00152724. Before their
participation, all subjects were informed of the methods and proce-
dures and gave their written informed consent to participate. Eligible
subjects were enrolled after medical interview and investigations,
including a normal electrocardiogram, an upper/lower limb Doppler
velocimetry, and a blood sample to confirm that platelet function was
normal, according to our laboratory standard. Volunteers were not
allowed to take any other drugs than those proposed in the protocol in
the 3 wk before enrollment and throughout the whole period of the
study.
Treatments
Using nonidentifiable capsules, three treatments were performed,
each over 4 days. Treatments consisted of a daily oral dose of either
1) aspirin (75 mg/day: Kardegic, Sanofi-Synthelabo, France) or
2) clopidogrel bisulfate (98 mg/day: Plavix, Sanofi-Synthelabo,
France) or 3) placebo (lactose 0.21 mg/day, Chemistry of Angers
Hospital, France), taken at 7:00 AM every morning. Previous studies
have shown that 98 mg of clopidogrel bisulfate per day induces a
significant inhibition of platelet aggregation induced by ADP within 3
to 5 days (8, 37).
The order of the treatments was chosen randomly, and subjects and
investigators were double blinded as to the nature of the treatment.
Experimental trials in the same subject were separated by a minimum
interval of 3 wk. Intake and efficacy of the drugs were assessed using
platelet aggregation tests.
Platelet Aggregation Study
A blood sample, taken from an antecubital vein at enrollment and
just before CIV assessment, was withdrawn into a tube containing 0.1
M sodium citrate (BD Vacutainer, Plymouth, UK).
Platelet aggregation was measured by light transmission (PACKS
4, Helena, Claremont, Ontario, Canada) in stirred (1,000 rpm) plate-
let-rich plasma. The platelet-rich plasma was prepared by the centrif-
ugation from whole blood at 1,000 g for 7 min and platelet-poor
plasma by the centrifugation of the platelet-rich plasma at 3,400 g for
15 min. The platelet count was adjusted to 250,000 platelets/l with
platelet-poor plasma; platelet-rich plasma, and platelet-poor plasma
were used to set light transmission to 0% and 100%, respectively.
Aggregation was measured as the slope of the aggregation after the
addition of the agonist and expressed as a percentage of total aggre-
gation per second.
Aggregation responses were determined in 0.3-ml sample of plate-
let-rich plasma. Aggregation was stimulated with 2 and 1 mol/l ADP
(Helena, Claremont, Ontario, Canada) to test the ADP pathway and
0.3 mg/ml arachidonic acid (Helena, Claremont, Ontario, Canada) to
test the COX pathway.
With aspirin, the inhibition of arachidonic acid-induced platelet
aggregation is almost 100%, while with clopidogrel, the inhibition of
ADP-induced aggregation never reaches 100%, is dose and time
dependent, and at steady state is in the range of 40 to 60% (33). Then,
the efficacy of treatments was defined as a decrease of at least 50% in
platelet aggregation induced by arachidonic acid and as a decrease of
at least 20% in platelet aggregation induced by ADP (as compared
with their reference values) for aspirin and clopidogrel, respectively,
compared with individual baseline values. Patients not fulfilling these
criteria were not enrolled in the study.
The aggregation study was not used to argue for the participation of
platelets in microvascular responses but was aimed at confirming that
any absence of drug effects on CIV was not related to an ineffective
dose or to nonadherence of the volunteers in following the treatment
regimen.
Protocol 1
Nine healthy volunteers (7 males, 2 females), 27.6  2.8 (mean 
SD) years, height: 177.3  7.2 cm, weight: 68.9  7.4 kg were
enrolled in the first protocol.
Treatments were started 4 days before each experiment. Subjects
received aspirin, clopidogrel, and placebo treatments in a double-
blinded random order, with an interval of at least 3 wk between drug
treatments. The last capsule was taken at 7:00 AM on the day of
microvascular investigation. Blood sample collections were per-
formed at 9:00 AM to assess platelet aggregation and drug efficiency.
The microvascular studies for CIV were started between 9:10 AM and
9:30 AM. Thus, the last drug capsule intake took place2.25 h before
the start of the microvascular tests.
To avoid any local inflammatory effects of the venous puncture on
CIV, assessment was performed on the arm contralateral to blood
sampling.
Protocol 2
We aimed to test whether any impairment of CIV seen in protocol
1 resulted from an impairment of endothelium-dependent vasodilation
by aspirin, although at such very low doses that endothelial function
was expected to be unimpaired. Previous studies have shown that,
after aspirin intake, endothelial cells fully recover their cyclooxygen-
ase activity within 24 h (18, 19, 22). Thus if any impairment of
endothelial or smooth muscle COX had occurred despite the very low
dose of aspirin used in protocol 1, a 24-h delay in the assessment of
CIV would allow for the restoration of endothelial and smooth muscle
cell cyclooxygenase activity, whereas platelet aggregation would
continue to be inhibited. Therefore, in protocol 2, we tested ACh-
mediated vasodilation and postocclusive hyperemia, and treatment
intake was staggered earlier than in protocol 1, beginning 5 days and
stopping 26 h before the experiment.
Ten healthy young men, 23.0  2.8 years, 179.2  5.1 cm, 73.4 
9.2 kg, participated in this second protocol. Volunteers enrolled in the
first protocol were not allowed to participate in protocol 2.
A first CIV test was performed before treatment. This first test was
referred as the test “at enrollment” throughout the text, to avoid any
confusion with the terminology for baseline values obtained in the
first 2 min of each protocol. Subjects were then given either aspirin or
placebo in a double-blind manner.
Blood sample collections were performed at 9:00 AM to assess
platelet aggregation and drug efficacy. Microvascular investigations
were started within half an hour of the blood sampling and performed
on the contralateral arm to avoid any variation arising from potential
inflammatory effects on the arm used for sampling.
Assessment of CIV (Protocols 1 and 2)
CIV assessments were performed in a quiet air-conditioned room
with the ambient temperature set at 24  1°C. The subjects were
placed supine and rested for 15 min before data collection. We studied
the effect on SkBF of anodal current application, through deionized
water, on the volar aspect of the forearm. This technique has been
extensively described elsewhere (10). Two laser-Doppler multifiber
probes were used and connected to a laser-Doppler flowmeter (Peri-
flux PF4001, Perimed, Sweden). One probe (“active” probe: PF481.1,
Perimed, Sweden) was specially designed to allow for SkBF mea-
surements. The “active” probe has a circular chamber, allowing for
the positioning of an adhesive patch designed with a sponge of 1.2
cm2 area (PF383, Perimed, Ja¨rfa¨lla, Sweden). Before each experi-
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ment, the sponge was wet with 0.2 ml of deionized water and the
patch, combined with the “active” probe, was fixed to the skin. The
patch allowed for current application through the anodal terminal of a
9-V current intensity-regulated supplier (Periiont, Micropharmacol-
ogy System, PF382 Perimed). The cathodal terminal was connected to
an Ag/AgCl disposable electrode (Care 610, Kendall, Neustadt, Ger-
many) fixed 5 cm from the “active” probe. The second laser Doppler
probe (“reference” probe: PF408, Perimed), positioned on the same
volar aspect of the skin forearm, was used to assess the stability of
SkBF at an adjacent unstimulated site. The current application con-
sisted of the transcutaneous delivery of two consecutive 1-min periods
of 0.1-mA anodal current separated by a 10-min interval. The first
current application is known to induce little vasodilator response,
whereas the second current application induces an ample aspirin-
sensitive vasodilation (11). Following the second period of current
application, data were recorded for 10 min.
Assessment of Endothelial Function (Protocol 2 Only)
Simultaneously to CIV testing, an additional identical laser-Dop-
pler multifiber probe was used to assess ACh-mediated vasodilation
(PF481.1, Perimed). The technique has been described elsewhere (26,
44). The sponge of the electrode (PF383, Perimed, Sweden) was wet
with 0.2 ml of ACh solution (2% in deionized water), followed by an
anodal stimulation (9V, 0.08 mA/cm2, 20 s, Periiont, Micropharma-
cology System, PF382 Perimed). The cathodal electrode (Care 610,
Kendall, Neustadt, Germany) was placed 5 cm from the anodal
electrode.
For the second protocol, a tourniquet was placed proximal to the
position of the electrodes. It was used to cause 3 min of ischemia of
the forearm by applying supra-systolic pressure for 3 min. Ischemia
was started 10 min after the end of the second period of anodal current
application, and postocclusive hyperemia was recorded for an addi-
tional 15 min. This was used to assess the maximal values during
reperfusion, which has been shown to reflect endothelial function
within an individual across a treatment period in a reproducible
manner (45).
Pressure Measurement
Throughout the experiments, systemic arterial blood pressure was
recorded using a Finapres 2350 (Ohmeda, Englewood CO) positioned
on the 2nd or 3rd finger of the hand contralateral to the sites of SkBF
measurements.
Recordings and Data Analysis
The signals from the laser-Doppler flowmeters and Finapres were
recorded on a computer via an analog to digital converter (Biopac
System, Goleta, CA) with a sample frequency of 20 Hz. Data
collection started with a 2-min baseline period before the onset of
current application.
Because of instantaneous variability resulting from vasomotion, all
individual laser-Doppler flowmeter signals were averaged over 15-s
intervals throughout each experiment (for CIV, ACh-mediated vaso-
dilation, and postocclusive hyperemia). To take into account possible
changes in systemic hemodynamic conditions, SkBF was indexed as
cutaneous vascular conductance calculated as the ratio of SkBF,
expressed in arbitrary units (AU), to mean arterial blood pressure
(mmHg) over the same 15-s interval. Vascular conductance was then
expressed in AU/mmHg. Baseline values were calculated as the
average over the 1-min baseline period prior to the onset of the first
current application. All results were expressed as a percentage of
baseline conductance (%Cb).
For CIV, we analyzed the maximal vascular conductance recorded
following the second period of current application. For ACh ionto-
phoresis, we studied both the peak conductance (immediately after
stimulation) and the plateau conductance (20 min later), since we
previously reported that the plateau, but not the peak, was prostaglan-
din dependent (14). For postocclusive hyperemia, we recorded the
peak value for vascular conductance following deflation of the occlu-
sion cuff.
Statistical Analyses
To detect a decrease of CIV from 600%Cb to 200%Cb with 150 SD,
power calculations indicated that the minimal number of subjects to
be enrolled for   0.05 and a 80% power was 6.
Data were expressed as means SE. ANOVA with Tukey post hoc
was used to compare treatments one to another in all experiments.
Statistical analyses were performed with SPSS V13.0 (LEAD Tech.,
Charlotte, NC). Further, the Pearson test was used to compare the
value at enrollment and under placebo in protocol 2 to estimate the
test retest reproducibility of the experiments. A two-tailed P value less
than 0.05 was considered significant in all statistical analyses.
RESULTS
Protocol 1
Assessment of platelet aggregation. As shown in Table 1,
aspirin treatment induced a complete abolition of the arachi-
donic acid-induced platelet aggregation compared with placebo
but had no significant effect on the 2 and 1 mol/l ADP-
induced platelet aggregation. Clopidogrel treatment induced a
significant decrease of the 2 and 1 mol/l ADP-induced plate-
let aggregation (on the average 48 to 70% from value at
enrollment). A significant decrease of 50% in the aggrega-
tion to arachidonic acid was also noted. No significant differ-
ence was found between the values for platelet aggregation
observed under placebo and the values at enrollment.
Assessment of CIV. Compared with baseline values, no
significant changes were observed for control SkBF at the
reference probe or in mean arterial blood pressure during these
experiments. No differences were found in vascular conduc-
tance values at rest: 0.12 0.03, 0.23 0.14, and 0.17 0.09
AU/mmHg among the placebo, aspirin, and clopidogrel trials,
respectively. The two 1-min anodal current applications re-
sulted in significant increases of SkBF corresponding to a CIV
of 822  314, 313  144, and 746  397%Cb with placebo,
aspirin, and clopidogrel, respectively (P  0.01 vs. rest) as
shown in Fig. 1. The CIV observed following aspirin treatment
was less than the one observed following both placebo and
clopidogrel (P  0.05). The CIV after clopidogrel was not
significantly different from placebo (P  0.923).
Protocol 2
Assessment of platelet aggregation. As shown in Table 2,
aspirin treatment induced a complete abolition of the arachi-
donic acid-induced platelet aggregation in six subjects. In the
Table 1. Aggregation velocity at enrollment and under
treatment in experiment 1
At Enrollment Clopidogrel Aspirin Placebo
2 M ADP 8318 5117*† 8711 8416
1 M ADP 5317 2114*† 6011 5112
Arachidonic acid 7727 4117* 00*‡ 6317
Values are expressed as means  SE. *P  0.05 from values at enrollment.
†P  0.05 from values under aspirin and placebo. ‡P  0.05 from values
under clopidogrel and placebo.
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other four subjects, the arachidonic acid-induced platelet ag-
gregation was severely impaired (10% of the value at enroll-
ment), which seems consistent with the 10% resynthesis of
platelets after 1 day without aspirin intake. When compared
with placebo and the values at enrollment, the effect of aspirin
on arachidonic acid-induced platelet aggregation was signifi-
cant (P 0.05). Placebo showed no difference from the values
at enrollment.
Assessment of CIV. Compared with baseline values, no
significant changes were observed either for control SkBF at
the reference probe or for mean arterial blood pressure during
these experiments. Figure 2 represents the mean of the vascular
conductances during the second protocol for the anodal current
application with deionized water. No differences were found in
vascular conductance values at rest: 0.10  0.05, 0.10  0.05,
and 0.11  0.03 AU/mmHg for the values at enrollment, with
aspirin and with placebo, respectively. As in protocol 1, the
two 1-min anodal current applications were followed by an
abrupt vasodilation for both the experiment at enrollment and
with placebo (Fig. 2), whereas the vasodilator response was
significantly impaired with aspirin pretreatment. Peak re-
sponses after the two periods of current application were 915
493, 300  99, and 916  528%Cb for the values at enroll-
ment, with aspirin and with placebo, respectively. No signifi-
cant difference was seen between placebo and values at enroll-
ment and a significant correlation was found between individ-
ual values at enrollment and under placebo: r 0.64 P 0.05.
A significant difference was observed between aspirin and
either placebo or values at enrollment (P  0.05), thus con-
firming the results observed in protocol 1.
Assessment of endothelium-dependent vasodilation. No dif-
ferences were found in vascular conductances at rest: 0.14 
0.08, 0.12  0.06, and 0.09  0.04 AU/mmHg for the values
at enrollment, with aspirin and with placebo, respectively. The
peak values following ACh iontophoresis were similar at
enrollment, with aspirin and with placebo: 374  145, 322 
74, and 365 104%Cb, respectively (no significant differences
were detected among treatments, P  0.05). Figure 3 repre-
sents the mean  SE levels of peak vasodilation during ACh
iontophoresis. No difference was observed for the plateau
values following ACh iontophoresis: 248  117, 167  40,
and 176  57%Cb for the values at enrollment, with aspirin
and with placebo, respectively. A significant correlation was
found between individual values at enrollment and with pla-
cebo r  0.89 P  0.001.
Fig. 2. Values are expressed as means  SE for responses of maximal
cutaneous vascular conductance to two consecutive applications of 1-min
monopolar anodal current (CIV) at enrollment and following aspirin or placebo
in protocol 2. Results are presented as a percentage from baseline value.
Fig. 3. Values are expressed as means  SE for responses of maximal
cutaneous vascular conductance during ACh iontophoresis at enrollment and
following aspirin or placebo in protocol 2. Results are presented as a percent-
age from baseline value.
Table 2. Aggregation velocity at enrollment and under
treatment in experiment 2
At Enrollment Aspirin Placebo
2 M ADP 16922 18323 17813
1 M ADP 9925 12021 11528
Arachidonic acid 16628 68* 17611
Values are expressed as means  SE. *P  0.05 from values at enrollment
and placebo.
Fig. 1. Values are expressed as means  SE for responses of maximal
cutaneous vascular conductance to two consecutive applications of 1-min
monopolar anodal current (CIV) following placebo, aspirin, or clopidogrel in
protocol 1. Results are presented as a percentage from baseline value.
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Finally, as shown in Fig. 4, we found no difference in the
post-occlusive reactive hyperemia between the three groups.
Peak values were 545  242, 491  137, and 661  248%Cb,
respectively, for the values at enrollment, under aspirin and
under placebo. A significant correlation was found between
individual values at enrollment and under placebo: r  0.85
P  0.002.
DISCUSSION
It is generally accepted that platelets participate in vasocon-
striction when activated. Nonetheless, physiological models
suggest that platelets might also be involved in the vasodilator
mechanisms observed during neurogenic inflammation. How-
ever, to date, no in vivo evidence existed for a platelet-induced
vasodilation, specifically in humans. There are two major
findings relevant to this issue from the present study. In
protocol 1, low-dose aspirin treatment significantly decreased
CIV, whereas clopidogrel did not. Thus, if platelets are in-
volved in CIV (a model of neurogenic inflammation), it is
likely through the COX and not through the ADP pathway. The
second protocol confirmed that impairment of CIV occurred,
while ACh-mediated vasodilation and postocclusive hyper-
emia were preserved.
Following protocol 1, the fact that CIV was impaired under
aspirin in this study is consistent with previous studies in which
we used a single oral high dose of aspirin (10–12). Because
this high dose of aspirin induces a systemic inhibition of COX,
the identification of the origin of the COX involved in CIV was
not possible. In contrast to the high dose, aspirin given at very
low doses spares or minimally influences the vascular synthesis
of prostaglandins (17, 43). Indeed, at low doses of aspirin (up
to 325 mg daily), the systemic vascular endothelium undergoes
minimal exposure to aspirin due to its extensive presystemic
hepatic metabolism, whereas platelets undergo much greater
exposure (30). In parallel to COX inhibition, aspirin increases
lipoxygenase-derived metabolites; that is, leukotrienes (27).
Most leukotrienes exhibit endothelial-dependent relaxation
properties (38). Thus, it is unlikely that the decreased vasodi-
lation to CIV under aspirin is due to the effect of the drug on
leukotrienes bioavailability. Besides its inhibition of the COX
pathway (17, 34, 43), it has been suggested that aspirin may
interfere with the ADP-induced platelet aggregation (7, 24).
However, we observed no apparent change in the platelet
aggregation response to ADP with aspirin treatment.
Clopidogrel is a new drug in the recently developed class of
thienopyridine derivatives used to block ADP receptors on
platelets, blockade that results in an inhibition of platelet
aggregation. The active metabolite of clopidogrel has been
described as having a pharmacodynamic pattern quite similar
to that of aspirin, causing the cumulative inhibition of platelet
aggregation on repeated daily administration (32). Both the
cumulative nature of the inhibitory effects and the slow rate of
recovery of platelet function under clopidogrel cause a perma-
nent defect in a platelet protein that is not reversed during the
24-h dosing interval and can only be replaced as a function of
platelet turnover (32). Clopidogrel did not significantly impair
anodal CIV, whereas low-dose aspirin did. This occurred
although the efficacy of our treatment was in accordance with
the maximum inhibitory effects of clopidogrel on ADP-in-
duced aggregation observed at steady-state optimal clopidogrel
treatment (33). Platelet aggregation to arachidonic acid was
significantly decreased under clopidogrel. This latter finding is
consistent with previous reports (4, 35) but, to date, remains
unexplained. One possible explanation relates to the observa-
tion that the ADP pathway modulates platelet activation me-
diated by other physiological agonists (9, 28).
In protocol 2, the 26 h between the last aspirin intake and
microvascular experiments were assumed to allow for a com-
plete recovery of endothelial COX synthesis, if any impairment
of this synthesis had occurred in protocol 1. As previously
discussed, endothelial prostaglandin synthesis was expected to
be unimpaired at very low aspirin doses (in the range of 40–80
mg) but not at higher doses (17, 43). Previously, dosages of
486 to 500 mg aspirin were used to block endothelial cyclo-
oxygenase in vivo in conduit vessels (2, 21). In the microcir-
culation 1,000 mg aspirin consistently impairs the late phase of
ACh-mediated vasodilation (14). As a result of the very low
dose used and of the delay from the last aspirin intake in
protocol 2, no apparent impairment of endothelium-dependent
vasodilation was observed, whereas CIV was impaired. Thus
the impairment of CIV did not result from endothelial COX
blockade.
The absence of effect of clopidogrel and the inhibitory effect
of 75 mg of aspirin on CIV (even 26 h after the last dose),
suggest that platelets could be involved in CIV but via the
COX rather than the ADP pathway. The absence of CIV under
aspirin in protocol 2, while aggregation was partly restored,
also suggests that partial residual platelet function “normaliz-
ing” CIV was not the cause for the absence of CIV impairment
with clopidogrel in protocol 1.
Study limitation. The possible platelet involvement sug-
gested by the present results is consistent with the absence of
effect of the specific COX-2 inhibitor (celecoxib) on CIV, as
previously observed (39), since it is well known that most
platelet prostaglandins are synthesized by COX-1. In principle,
antiplatelet agents, such as aspirin or clopidogrel, do not fully
inhibit activation of platelets stimulated by agents other than
arachidonic acid or ADP (42). It cannot be excluded that the
persistent moderate response under aspirin and the almost
Fig. 4. Values are expressed as means  SE for responses of maximal
cutaneous vascular conductance during postocclusive hyperemia to 3-min
ischemia, at enrollment and following aspirin or placebo in protocol 2. Results
are presented as a percentage from baseline value.
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normal response under clopidogrel resulted from the activation
of platelets through another pathway.
Could the fact that clopidogrel did not significantly impair
CIV be a type 2 error? This is probably not the case since the
P value is far from significance, and it is thus unlikely that
increasing the number of observations could have allowed
reaching the significant level consistently with the number of
subjects’ calculation.
Last, it is notable that patients included in the first protocol
were different from those participating in protocol 2. This does
not allow for the direct comparison of the results from protocol
1 to the results of protocol 2. Nevertheless, this confirmed that
the impairment of CIV observed with aspirin was not specific
of the population studied in protocol 1.
Perspectives and Significance
These findings indicate that platelets are involved in the
neurovascular vasodilation triggered by galvanic current appli-
cation, mainly through the COX pathway. Aspirin and clopi-
dogrel inhibit platelet aggregation by different pharmacody-
namic mechanisms. The glycoprotein IIb/IIIa (GP IIb/IIIa)
receptor serves as the final common pathway for platelet
aggregation (25). Binding of GP IIb/IIIa receptor results in a
highly selective and efficient inhibition of platelet aggregation,
independent of the particular platelet-activating mechanism.
The effect of GP IIb/IIIa inhibitors on CIV might allow for a
more specific demonstration of platelet involvement in this
model. However, the risk of severe thrombocytopenia from GP
IIb/IIIa inhibitors precludes its acceptance for use in healthy
subjects. Furthermore, inhibition of the platelet GP IIb/IIIa
receptor enhances the release of platelet-derived nitric oxide
(6), a potent vasodilator that could interfere with the expected
decreased response to galvanic current application.
In the CAPRIE study, clopidogrel was found to have a
significant benefit over low-dose aspirin, specifically in PAD
patients, in terms of cardiovascular complications (5). More
recently, an inhibitory effect of aspirin but not clopidogrel on
arteriogenesis has been shown (20). A relationship of these
results to the preservation under clopidogrel but not under
aspirin of neurovascular interactions involving platelets is a
fascinating but unproven hypothesis for future studies.
Last, our results are of potential clinical significance. Low-
dose aspirin is largely used in primary prevention among
patients with high risk of cardiovascular disease. There is a
high correlation between neuropathy and foot ulcer in diabetic
patients. The inhibitory effect of aspirin, even at a very low
dose, on the neurovascular response to primary afferent fiber
activation could be a major disadvantage of this drug in such
patients.
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